The upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting will be a digital event from June 4-8, featuring 48 educational and scientific sessions and showcasing what is possible when the cancer care community comes together to advance cancer research, treatment, and patient care.
The event will allow real-time engagement, a live Q&A, and learning opportunities for attendees. From June 4 there will be access to on-demand content and presentations from 175 sessions, featuring presentations from poster and poster discussion sessions, clinical science symposia and dynamic education sessions.
HUTCHMED has announced that new analyses and updates on the ongoing studies of savolitinib, surufatinib, fruquintinib and HMPL-306 will be presented. Aspects of these clinical data disclosures, alongside its PD-1/L1 combination study strategy and corporate update, will be discussed as part of the previously announced call and webcast on Wednesday, May 26 at 9am EDT.
AstraZeneca will be presenting more than 100 abstracts, and featuring 21 approved and potential new medicines across the company’s oncology portfolio, with four abstracts selected as late-breakers, 12 oral presentations and one plenary presentation.
Gilead Sciences and Kite, a Gilead Company, have announced that sixteen abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented, including two presentations, an expansion on the clinical profiles of Gilead’s antibody-drug conjugate (ADC) sacituzumab govitecan-hziy (Trodelvy), as well as how Kite’s chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (Yescarta) and autologous anti-CD19-transduced CD3+ cells (Tecartus, formerly KTE-X19) can be used across a range of cancers, including in existing indications and for investigational uses.
Sanofi will showcase data from its oncology pipeline, including early clinical data for investigational oral selective oestrogen receptor degrader (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer; data that reinforce Libtayo (cemiplimab-rwlc) as a standard of care in advanced non-melanoma skin cancer and advanced non-small cell lung cancer, including new data in historically underrepresented patients with brain metastases; and longer term data and new analyses for Sarclisa (isatuximab-irfc) further strengthen efficacy profile, including for elderly patients and patients with high-risk cytogenetic abnormalities.